Analysis of Health Care Stocks at Risk for a March Slide

March 28, 2024, marks a pivotal moment for investors eyeing the health care sector. Five stocks are gleaming like sirens, tempting traders with their momentum but possibly harboring a darker warning beneath the surface.

The Relative Strength Index (RSI) is casting a revealing light on these potential hazards. Comparing a stock’s strength on its good days to that on its bad days, this indicator peels away the glamour to expose the truth behind the price action. Any RSI value above 70 typically signifies perilous waters for investors, according to Benzinga Pro.

Let’s dissect the latest list of overbought giants in this sector, each potentially teetering on the edge of a precipice.

The Pennant Group, Inc. (PNTG)

• On Feb. 28, Pennant Group shocked the market with robust quarterly sales. Brent Guerisoli, the company’s CEO, beamed with pride, stating, “We’re thrilled with our robust finish in 2023, paving the way for a promising 2024 ahead.” Pennant’s stock soared approximately 18% in the past month, boasting a glorious 52-week high of $20.50.
• RSI Value: 90.15
• PNTG Price Action: Pennant Group’s shares climbed 1.7% to a close at $19.84 on Wednesday.

Mesoblast Limited (MESO)

• On March 25, Mesoblast received an epiphany from the FDA, greenlighting its dream as clinical data from the Phase 3 study MSB-GVHD001 painted a promising future for remestemcel-L in pediatric patients facing a dire health struggle. The stock sky-rocketed by 54% in the past five days, crowning it with a 52-week high of $10.24.
• RSI Value: 71.74
• MESO Price Action: Mesoblast’s shares stumbled 11.2%, closing at $3.49 on Wednesday.

ARS Pharmaceuticals, Inc. (SPRY)

• On March 21, ARS Pharmaceuticals unveiled a pleasant surprise with better-than-expected fourth-quarter results. The company’s stock danced 13% higher in the past five days, adorning it with a 52-week high of $10.20.
• RSI Value: 70.11
• SPRY Price Action: ARS Pharmaceuticals’ shares slipped 0.4% to close at $9.96 on Wednesday.

Neuronetics, Inc. (STIM)

• On March 25, Neuronetics had a fairy-tale ending as NeuroStar Advanced Therapy received the FDA’s blessing as a premier add-on treatment for adolescents battling depression. The stock soared an unbelievable 62% in the past month, reaching a dazzling 52-week high of $4.99.
• RSI Value: 72.16
• STIM Price Action: Neuronetics’ shares rose 0.8% to a close at $4.80 on Wednesday.

Inozyme Pharma, Inc. (INZY)

• On March 26, Inozyme Pharma unwrapped a gift for investors, hinting at topline data from its ongoing Phase 1/2 trial of INZ-701. The stock fluttered 22% higher in the past five days, twinkling with a 52-week high of $7.56.
• RSI Value: 71.56
• INZY Price Action: Inozyme Pharma’s shares climbed a jubilant 9% to a close at $7.39 on Wednesday.

Read More: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday